Deals


  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Nemes Laszlo via Getty Images
    Image attribution tooltip

    Roche, Adaptimmune part ways on cell therapy research

    The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.

    By April 12, 2024
  • NK Cell (Natural Killer Cell) Attacking a Cancer Cell
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Emerging biotech

    Century buys a startup, raises funding in cell therapy expansion

    The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.

    By April 11, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Blog
    Image attribution tooltip
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A.

    By BioPharma Blog staff
  • Vertex CEO Reshma Kewalramani
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex to buy kidney disease drugmaker Alpine for $4.9B

    A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.

    By Updated April 11, 2024
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to acquire Shockwave Medical for $13.1B

    The deal comes just over a week after The Wall Street Journal reported the companies were discussing a merger.

    By Ricky Zipp • Updated April 5, 2024
  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry

    The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.

    By Kristin Jensen • April 3, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Acorda files for bankruptcy, reveals asset sale plan

    Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

    By April 2, 2024
  • Claudia Ulbrich, CEO, Cardior Pharmaceuticals
    Image attribution tooltip
    Permission granted by Cardior
    Image attribution tooltip

    ‘The heart is back,’ says Cardior CEO, as Novo’s $1B deal boosts field

    Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior head Claudia Ulbrich.

    By Michael Gibney • March 28, 2024
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie to buy immune drug developer Landos

    Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

    By March 25, 2024
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Novo to acquire heart failure drug in $1B deal for Cardior

    Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.

    By March 25, 2024
  • Thermo Fisher Scientific
    Image attribution tooltip
    Courtesy of Thermo Fisher Scientific
    Image attribution tooltip

    Thermo Fisher, Bayer partner to develop companion diagnostics

    The companies aim to identify potential patients for Bayer’s precision cancer therapies and increase access to the treatments.

    By Nick Paul Taylor • March 21, 2024
  • Prostate cancer cells, 3D illustration. Prostate cancer awareness image
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion

    The deal hands AstraZeneca a prostate cancer drug that’s designed differently than Novartis’ fast-selling Pluvicto and currently in mid-stage testing.

    By March 19, 2024
  • The East facade of the Capitol Building in Washington DC.
    Image attribution tooltip
    dkfielding via Getty Images
    Image attribution tooltip

    BIO changes stance, backs bill to limit China’s role in US biotech

    Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.

    By March 14, 2024
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt

    The deal gives AstraZeneca a prospect in late-stage testing for parathyroidism and bolsters a rare disease portfolio that mainly consists of drugs from Alexion.

    By Kristin Jensen • March 14, 2024
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip

    Boehringer, Sosei Heptares team up in schizophrenia drug deal

    Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

    By March 11, 2024
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead bets on ‘trispecifics’ in latest cancer drug deal

    A small partnership with Merus adds to Gilead’s string of cancer dealmaking, which, so far, has not paid off for the large biotech.

    By March 6, 2024
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Abingworth invests in Trodelvy development in deal with Gilead

    One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.

    By Kristin Jensen • Feb. 29, 2024
  • People walk past a building in New York City
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    NGM to go private through deal with investment firm

    The deal would mark a retreat from public markets for the once notable biotech, which was forced to cut staff last year to save cash after trial setbacks.

    By Feb. 26, 2024
  • FTC
    Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
    Image attribution tooltip

    AbbVie’s Cerevel deal hits an uncommon roadblock

    A “second request” from the Federal Trade Commission could protract the timing of AbbVie’s proposed acquisition, which is slated to close around the middle of the year.

    By Feb. 20, 2024
  • Blue double exposure of money coins stacking with bar graph for financial and investment business concept.
    Image attribution tooltip
    Dilok Klaisataporn
    Image attribution tooltip

    BioAge raises $170M to back Phase 2-ready obesity drug

    BioAge’s Series D will fund a study combining its medicine with Eli Lilly’s Zepbound, a strategy the company hopes could help people lose weight while maintaining muscle mass.

    By Feb. 13, 2024
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead to buy CymaBay in $4.3B deal for liver disease drug

    The proposed acquisition is a bet on CymaBay’s drug seladelpar, which is now under FDA review in a chronic liver disease called primary biliary cholangitis.

    By Feb. 12, 2024
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    BridgeBio sells partial rights to dwarfism drug for $100M

    The deal hands Kyowa Kirin rights in Japan to the drug, which is emerging as a potential rival to BioMarin’s marketed medicine Voxzogo.

    By Feb. 7, 2024
  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca to invest $300M in US cell therapy plant

    The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.

    By Kristin Jensen • Feb. 7, 2024
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte

    The deals would hand Novartis a myelofibrosis drug with uncertain regulatory prospects and Incyte a marketed lymphoma medicine that hasn’t sold well.

    By Feb. 6, 2024
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo Holdings to buy contract drugmaker Catalent for $16.5B

    In a related deal, Novo Holdings subsidiary Novo Nordisk will buy three major Catalent factories for $11 billion as it works to keep pace with demand for its obesity and diabetes medicines.

    By Feb. 5, 2024
  • Valneva sells regulatory ‘fast pass’ for $103M

    The company said it will invest the sale proceeds into testing of an experimental Lyme disease shot and of Ixchiq, its new chikungunya vaccine.

    By Feb. 5, 2024